Q3 Revenue Hits $24.3M With 72.8% Adjusted Gross Margin
SOPH sits 84% above its 52-week low of $3.83.
Summary
SOPHiA GENETICS reported Q3 revenue of $24.3 million, up on US market strength, and an adjusted gross margin of 72.8%. The quarter's loss came to 24 cents a share. The brief carries no year-over-year comparison and no guidance update, so the market has little to anchor the print against beyond the loss figure. The margin level is the more informative number here — gross margin in the low 70s is consistent with a software-heavy data business rather than a pure diagnostics lab. Context: the company reaffirmed FY26 guidance and raised $14.5M through its ATM in the May 6-K, so any read-through on cash runway depends on whether this quarter's revenue pace supports that plan.
At the time of this announcement, SOPH was trading at $7.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $605.3M. The 52-week trading range was $3.83 to $8.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.